



The Utah Society of Health-System Pharmacists Presents:
 Resident Continuing Pharmacy Education Series
 Spring 2020

Target Audience: Pharmacists, pharmacy technicians, and pharmacy students

Date/Time Location	Presenter	Title, Objectives & ACPE UAN			
Saturday, April 11 8:00am *Webex Only*	Michael Konietzko, PharmD Mentor: <i>Nick Cox PharmD, BCACP, Assistant Professor (Clinical) University of Utah</i>	<p style="text-align: center;">Outpatient Treatment of Opioid Use Disorder (0.1CEU) #S-0167-0000-20-016-L01-P/T</p> <table border="0" style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top;"> <u>Pharmacist Objectives:</u> 1. Define opioid use disorder 2. Discuss the epidemiology behind opioid use disorder in the United States 3. Compare the medications used for the outpatient treatment of opioid use disorder 4. Design an outpatient treatment regimen for opioid use disorder 5. Recognize drugs in the research pipeline for the treatment of opioid use disorder </td> <td style="width: 50%; vertical-align: top;"> <u>Technician Objectives:</u> 1. Discuss outpatient treatment options for opioid use disorder 2. Recognize drugs in the research pipeline for the treatment of opioid use disorder 3. Differentiate which treatment options can be used in special populations </td> </tr> </table>		<u>Pharmacist Objectives:</u> 1. Define opioid use disorder 2. Discuss the epidemiology behind opioid use disorder in the United States 3. Compare the medications used for the outpatient treatment of opioid use disorder 4. Design an outpatient treatment regimen for opioid use disorder 5. Recognize drugs in the research pipeline for the treatment of opioid use disorder	<u>Technician Objectives:</u> 1. Discuss outpatient treatment options for opioid use disorder 2. Recognize drugs in the research pipeline for the treatment of opioid use disorder 3. Differentiate which treatment options can be used in special populations
<u>Pharmacist Objectives:</u> 1. Define opioid use disorder 2. Discuss the epidemiology behind opioid use disorder in the United States 3. Compare the medications used for the outpatient treatment of opioid use disorder 4. Design an outpatient treatment regimen for opioid use disorder 5. Recognize drugs in the research pipeline for the treatment of opioid use disorder	<u>Technician Objectives:</u> 1. Discuss outpatient treatment options for opioid use disorder 2. Recognize drugs in the research pipeline for the treatment of opioid use disorder 3. Differentiate which treatment options can be used in special populations				
Saturday, April 11 9:00am *Webex Only*	Bryn Lindley, PharmD Mentor: <i>Kyle Turner, PharmD BCACP Clinical Pharmacist, University of Utah Health</i>	<p style="text-align: center;">Perfecting the Process: Implementing the Pharmacist Patient Care Process Across Practice Settings (0.1CEU) #A-0167-0000-20-007-L04-P/T</p> <table border="0" style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top;"> <u>Pharmacist Objectives:</u> 1. Define the Pharmacist Patient Care Process 2. Apply the Pharmacist Patient Care Process to your current practice area 3. Develop an initial plan for implementation into your practice and precepting </td> <td style="width: 50%; vertical-align: top;"> <u>Technician Objectives:</u> 1. Define the Pharmacist Patient Care Process 2. Illustrate how the Pharmacist Patient Care Process can be applied to technician practice 3. Integrate the Pharmacist Patient Care Process into your current practice area </td> </tr> </table>		<u>Pharmacist Objectives:</u> 1. Define the Pharmacist Patient Care Process 2. Apply the Pharmacist Patient Care Process to your current practice area 3. Develop an initial plan for implementation into your practice and precepting	<u>Technician Objectives:</u> 1. Define the Pharmacist Patient Care Process 2. Illustrate how the Pharmacist Patient Care Process can be applied to technician practice 3. Integrate the Pharmacist Patient Care Process into your current practice area
<u>Pharmacist Objectives:</u> 1. Define the Pharmacist Patient Care Process 2. Apply the Pharmacist Patient Care Process to your current practice area 3. Develop an initial plan for implementation into your practice and precepting	<u>Technician Objectives:</u> 1. Define the Pharmacist Patient Care Process 2. Illustrate how the Pharmacist Patient Care Process can be applied to technician practice 3. Integrate the Pharmacist Patient Care Process into your current practice area				
Saturday, April 11 10:30am *Webex Only*	Alissa Chan, PharmD Mentors: <i>Lonnie Smith, PharmD, F.A.S.T Adrian Carlson, PharmD, BCPS Crystal Truax, PharmD, BCPS Bhanupriya Sirandas, PharmD, BCPS Breanna Clark, PharmD Clinical Pharmacists, Solid Organ Transplant, University of Utah Health</i>	<p style="text-align: center;">Baby on Board in Solid Organ Transplantation (0.1CEU) #A-0167-0000-20-008-L01-P/T</p> <table border="0" style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top;"> <u>Pharmacist Objectives:</u> 1. Develop an immunosuppressive regimen for transplant recipients who are interested in becoming pregnant 2. Distinguish immunosuppressive agents that can cross the placenta 3. Apply the mycophenolate REMS program into your pharmacy practice 4. Explain complications associated with pregnancy in solid organ transplant patients </td> <td style="width: 50%; vertical-align: top;"> <u>Technician Objectives:</u> 1. Identify immunosuppressive agents that require safe handling 2. Evaluate a transplant recipient's immunosuppressive regimen and distinguish medications that have the potential to harm the mother and/or fetus 3. Describe immunosuppressant and prophylactic regimens for pregnant and non-pregnant transplant recipients </td> </tr> </table>		<u>Pharmacist Objectives:</u> 1. Develop an immunosuppressive regimen for transplant recipients who are interested in becoming pregnant 2. Distinguish immunosuppressive agents that can cross the placenta 3. Apply the mycophenolate REMS program into your pharmacy practice 4. Explain complications associated with pregnancy in solid organ transplant patients	<u>Technician Objectives:</u> 1. Identify immunosuppressive agents that require safe handling 2. Evaluate a transplant recipient's immunosuppressive regimen and distinguish medications that have the potential to harm the mother and/or fetus 3. Describe immunosuppressant and prophylactic regimens for pregnant and non-pregnant transplant recipients
<u>Pharmacist Objectives:</u> 1. Develop an immunosuppressive regimen for transplant recipients who are interested in becoming pregnant 2. Distinguish immunosuppressive agents that can cross the placenta 3. Apply the mycophenolate REMS program into your pharmacy practice 4. Explain complications associated with pregnancy in solid organ transplant patients	<u>Technician Objectives:</u> 1. Identify immunosuppressive agents that require safe handling 2. Evaluate a transplant recipient's immunosuppressive regimen and distinguish medications that have the potential to harm the mother and/or fetus 3. Describe immunosuppressant and prophylactic regimens for pregnant and non-pregnant transplant recipients				

Date/Time Location	Presenter	Title, Objectives & ACPE UAN
Saturday, April 11 11:30am *Webex Only*	Mikayla Mills, PharmD Mentor: <i>Erica Marini, PharmD, MS, BCPS Clinical Pharmacist, Ambulatory Neurology University of Utah Health</i>	<p style="text-align: center;">Aura Ready for Migraine Medication Updates? (0.1CEU) #A-0167-0000-20-009-L01-P/T</p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> Describe current approaches for preventive and abortive treatment of migraine Compare and contrast new migraine treatment options Analyze appropriateness of use for new migraine agents Discuss accessibility and cost of new agents <p><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> Identify three signs and symptoms of a migraine Recognize brand and generic names of new migraine agents Evaluate one mechanism to assist patients in gaining accessibility to and financial assistance for new migraine agents
Tuesday, April 14 3:30pm *Webex Only*	Kelsea Zukauckas, PharmD Mentors: <i>Jessica Carey, PharmD Clinical Pharmacist, CVMU and Kimberly Terry, PharmD, BCCCP, BCPS Clinical Pharmacist, CVICU/SICU, University of Utah Health</i>	<p style="text-align: center;">Don't Go Mad, Lets Dive into LVADs: A LVAD Overview for Non-Cardiology Pharmacists (0.1CEU) #A-0167-0000-20-010-L01-P/T</p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> Identify the key components of INTERMAC score Describe the function of a left ventricular assist device (LVAD) and the differences between LVAD models Recognize the key factors that contribute to bleeding complications in LVAD patients Analyze the components of a LVAD patient's chart that would put them at risk for pump thrombosis or stroke Propose an empiric antibiotic plan for a patient with a LVAD drive line infection <p><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> Describe the function of a left ventricular assist device (LVAD) and the differences between LVAD models Recognize thalidomide as a REMS agent Select medications from a LVAD patient's medication administration record (MAR) that may require a prior authorization
Tuesday, April 14 4:30pm *Webex Only*	Bestis Wasef, PharmD Mentor: <i>Nick Lonardo, PharmD Clinical Coordinator-Surgery Clinical Adjunct Professor University of Utah</i>	<p style="text-align: center;">Pulmonary Embolism Management: Comparison of Guidelines (0.1CEU) #A-0167-0000-20-011-L01-P/T</p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> Describe the pathogenesis of a pulmonary embolism Define a pharmacist's role in the management of pulmonary embolism Recommend appropriate thrombolytic use based on patient characteristics Develop a plan and recommend appropriate anticoagulation for pulmonary embolism based on evidence-based data and guidelines <p><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> Define what a pulmonary embolism is Recognize which medications in the management of pulmonary embolism are considered STAT Identify the various formulations of the medications used in the management of pulmonary embolism Illustrate and reason through the correct handling of tPA during compounding and delivery
Thursday, April 16 3:30pm *Webex Only*	Kyle Finnerty, PharmD, MBA Mentor: <i>Brandon Tritle PharmD, BCIDP Clinical Pharmacist, Infectious Disease University of Utah Health</i>	<p style="text-align: center;">The Dodo's and Don'ts of Clostridium difficile (0.1CEU) #A-0167-0000-20-012-L01-P/T</p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> Recall the different testing options available for Clostridium difficile Analyze the utility of Clostridium difficile testing methods and results to distinguish between active infection and colonization Discuss how to interpret discordant testing results <p><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> Identify risk factors for developing C.diff infections Assess clinical signs and symptoms of active C.diff infections Evaluate the risks associated with improper treatment of C.diff

Date/Time Location	Presenter	Title, Objectives & ACPE UAN			
Thursday, April 16 4:30pm *Webex Only*	Sabrina Schneider, PharmD Mentors: <i>Tonya Smith, PharmD, BCPS;</i> <i>Jordan McPherson, PharmD, BCOP;</i> <i>Dan Sageser, PharmD, BCOP</i> <i>Clinical Pharmacists, Oncology</i> <i>Huntsman Cancer Institute</i>	<p style="text-align: center;">Revving Up and Spinning Out: Guideline Updates on Management of Immunotherapy Toxicity (0.1CEU) #A-0167-0000-20-013-L01-P/T</p> <table border="0" style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top;"> <u>Pharmacist Objectives:</u> 1. Compare and contrast available pharmaceutical treatments for common immune-related adverse events. 2. Recognize patient populations in which immune checkpoint inhibitors should be used cautiously or avoided altogether. 3. Design an appropriate management strategy for immune-related adverse events based on a patient case. </td> <td style="width: 50%; vertical-align: top;"> <u>Technician Objectives:</u> 1. Analyze a patient case to determine signs and symptoms of common immune-related adverse events. 2. Discuss how the preparation and administration of immunotherapy agents may vary from standard chemotherapy products. 3. Identify generic names and brand names of the currently approved immune checkpoint inhibitors. </td> </tr> </table>		<u>Pharmacist Objectives:</u> 1. Compare and contrast available pharmaceutical treatments for common immune-related adverse events. 2. Recognize patient populations in which immune checkpoint inhibitors should be used cautiously or avoided altogether. 3. Design an appropriate management strategy for immune-related adverse events based on a patient case.	<u>Technician Objectives:</u> 1. Analyze a patient case to determine signs and symptoms of common immune-related adverse events. 2. Discuss how the preparation and administration of immunotherapy agents may vary from standard chemotherapy products. 3. Identify generic names and brand names of the currently approved immune checkpoint inhibitors.
<u>Pharmacist Objectives:</u> 1. Compare and contrast available pharmaceutical treatments for common immune-related adverse events. 2. Recognize patient populations in which immune checkpoint inhibitors should be used cautiously or avoided altogether. 3. Design an appropriate management strategy for immune-related adverse events based on a patient case.	<u>Technician Objectives:</u> 1. Analyze a patient case to determine signs and symptoms of common immune-related adverse events. 2. Discuss how the preparation and administration of immunotherapy agents may vary from standard chemotherapy products. 3. Identify generic names and brand names of the currently approved immune checkpoint inhibitors.				
Saturday, April 18 8:00am *Webex Only*	Eric Wu, PharmD Mentor: <i>Jennifer Bishop, PharmD, BCPS,</i> <i>Residency Program Director,</i> <i>St. Mark's Hospital</i>	<p style="text-align: center;">Blockchain in Healthcare Technology (0.1CEU) #A-0167-0000-20-014-L04-P/T</p> <table border="0" style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top;"> <u>Pharmacist Objectives:</u> 1. Define and explain what is blockchain, where it is derived, and how it works 2. Recognize and list the potential benefits of blockchain technology in a healthcare setting 3. Apply the knowledge of blockchain technology to make informed decisions on how to implement this technology in healthcare systems </td> <td style="width: 50%; vertical-align: top;"> <u>Technician Objectives:</u> 1. Illustrate and recall the benefits of blockchain technology 2. Investigate the use of blockchain technology and propose future roles for pharmacy technicians to participate in managing informatics systems 3. Recognize where blockchain is being implemented and prepare technicians towards its adoption within healthcare </td> </tr> </table>		<u>Pharmacist Objectives:</u> 1. Define and explain what is blockchain, where it is derived, and how it works 2. Recognize and list the potential benefits of blockchain technology in a healthcare setting 3. Apply the knowledge of blockchain technology to make informed decisions on how to implement this technology in healthcare systems	<u>Technician Objectives:</u> 1. Illustrate and recall the benefits of blockchain technology 2. Investigate the use of blockchain technology and propose future roles for pharmacy technicians to participate in managing informatics systems 3. Recognize where blockchain is being implemented and prepare technicians towards its adoption within healthcare
<u>Pharmacist Objectives:</u> 1. Define and explain what is blockchain, where it is derived, and how it works 2. Recognize and list the potential benefits of blockchain technology in a healthcare setting 3. Apply the knowledge of blockchain technology to make informed decisions on how to implement this technology in healthcare systems	<u>Technician Objectives:</u> 1. Illustrate and recall the benefits of blockchain technology 2. Investigate the use of blockchain technology and propose future roles for pharmacy technicians to participate in managing informatics systems 3. Recognize where blockchain is being implemented and prepare technicians towards its adoption within healthcare				
Saturday, April 18 9:00am *Webex Only*	Brad Merrill, PharmD Mentor: <i>Jennifer Bishop, PharmD, BCPS,</i> <i>Residency Program Director,</i> <i>St. Mark's Hospital</i>	<p style="text-align: center;">Make the Time Count: The Development of Student Pharmacists (0.1CEU) #A-0167-0000-20-015-L04-P/T</p> <table border="0" style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top;"> <u>Pharmacist Objectives:</u> 1. Define the ACPE continuum of learning 2. Discuss common pitfalls for students and rotation sites 3. Outline your personal education philosophy 4. Compare current popular teaching philosophies 5. Develop plans to have quality assurance for your practice site </td> <td style="width: 50%; vertical-align: top;"> <u>Technician Objectives:</u> 1. Define the ACPE continuum of learning 2. Discuss common pitfalls for students and rotation sites 3. Outline your personal education philosophy 4. Compare current popular teaching philosophies 5. Develop plans to have quality assurance for your practice site </td> </tr> </table>		<u>Pharmacist Objectives:</u> 1. Define the ACPE continuum of learning 2. Discuss common pitfalls for students and rotation sites 3. Outline your personal education philosophy 4. Compare current popular teaching philosophies 5. Develop plans to have quality assurance for your practice site	<u>Technician Objectives:</u> 1. Define the ACPE continuum of learning 2. Discuss common pitfalls for students and rotation sites 3. Outline your personal education philosophy 4. Compare current popular teaching philosophies 5. Develop plans to have quality assurance for your practice site
<u>Pharmacist Objectives:</u> 1. Define the ACPE continuum of learning 2. Discuss common pitfalls for students and rotation sites 3. Outline your personal education philosophy 4. Compare current popular teaching philosophies 5. Develop plans to have quality assurance for your practice site	<u>Technician Objectives:</u> 1. Define the ACPE continuum of learning 2. Discuss common pitfalls for students and rotation sites 3. Outline your personal education philosophy 4. Compare current popular teaching philosophies 5. Develop plans to have quality assurance for your practice site				
Saturday, April 18 10:30am *Webex Only*	Shannon Tuttle, PharmD Mentor: <i>Nicholas Cox, PharmD, BCACP</i> <i>Assistant Professor (Clinical)</i> <i>University of Utah</i>	<p style="text-align: center;">Overdose of Options: An Overview of Abuse-Deterrent Opioid Formulations (0.1CEU) #A-0167-0000-20-006-L01-P/T</p> <table border="0" style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top;"> <u>Pharmacist Objectives:</u> 1. Review the development of abuse-deterrent opioid formulations and current availability 2. Analyze the data regarding the benefit of abuse-deterrent opioid formulations 3. Apply knowledge of abuse-deterrent formulations to pain management patient scenarios </td> <td style="width: 50%; vertical-align: top;"> <u>Technician Objectives:</u> 1. Identify the various available abuse-deterrent opioid products 2. Compare the cost and coverage of available abuse-deterrent opioid products to standard opioid products 3. Review opioid prescription requirements in the state of Utah </td> </tr> </table>		<u>Pharmacist Objectives:</u> 1. Review the development of abuse-deterrent opioid formulations and current availability 2. Analyze the data regarding the benefit of abuse-deterrent opioid formulations 3. Apply knowledge of abuse-deterrent formulations to pain management patient scenarios	<u>Technician Objectives:</u> 1. Identify the various available abuse-deterrent opioid products 2. Compare the cost and coverage of available abuse-deterrent opioid products to standard opioid products 3. Review opioid prescription requirements in the state of Utah
<u>Pharmacist Objectives:</u> 1. Review the development of abuse-deterrent opioid formulations and current availability 2. Analyze the data regarding the benefit of abuse-deterrent opioid formulations 3. Apply knowledge of abuse-deterrent formulations to pain management patient scenarios	<u>Technician Objectives:</u> 1. Identify the various available abuse-deterrent opioid products 2. Compare the cost and coverage of available abuse-deterrent opioid products to standard opioid products 3. Review opioid prescription requirements in the state of Utah				

Date/Time Location	Presenter	Title, Objectives & ACPE UAN		
Saturday, April 18 11:30am *Webex Only*	Josh McDonald, PharmD Mentors: <i>David Young, PharmD</i> <i>Internal Medicine Residency Program</i> <i>Director,</i> <i>University of Utah Health</i>	<p align="center">Escape the Vape: The Who, What, Where, When, Why, and How of E-cigarette or Vaping Associated Lung Injury (EVALI) (0.1CEU) #A-0167-0000-20-017-L01-P/T</p> <table border="0"> <tr> <td data-bbox="787 253 1669 464"> <u>Pharmacist Objectives:</u> 1. Understand current reporting standards by the CDC and FDA for EVALI events 2. Employ strategies to address questions about the hazards of e-cigarette use/vaping and patient’s perceived benefits 3. Distinguish EVALI from other pulmonary disease etiologies 4. Formulate a treatment plan for patients admitted to the hospital for EVALI </td> <td data-bbox="1704 253 2510 375"> <u>Technician Objectives:</u> 1. Define EVALI 2. Distinguish which products are associated with occurrences of EVALI 3. Recognize signs and symptoms of EVALI </td> </tr> </table>	<u>Pharmacist Objectives:</u> 1. Understand current reporting standards by the CDC and FDA for EVALI events 2. Employ strategies to address questions about the hazards of e-cigarette use/vaping and patient’s perceived benefits 3. Distinguish EVALI from other pulmonary disease etiologies 4. Formulate a treatment plan for patients admitted to the hospital for EVALI	<u>Technician Objectives:</u> 1. Define EVALI 2. Distinguish which products are associated with occurrences of EVALI 3. Recognize signs and symptoms of EVALI
<u>Pharmacist Objectives:</u> 1. Understand current reporting standards by the CDC and FDA for EVALI events 2. Employ strategies to address questions about the hazards of e-cigarette use/vaping and patient’s perceived benefits 3. Distinguish EVALI from other pulmonary disease etiologies 4. Formulate a treatment plan for patients admitted to the hospital for EVALI	<u>Technician Objectives:</u> 1. Define EVALI 2. Distinguish which products are associated with occurrences of EVALI 3. Recognize signs and symptoms of EVALI			

Registration, Info & Fees: All presentations are one hour. The cost is FREE for USHP members; otherwise, it is \$110 for pharmacists and \$25 for technicians to attend regardless of the number of hours or sessions attended. This fee can be paid online at www.ushp.org. If you are interested in joining USHP, please visit our website www.ushp.org and join online.

WebEx Meeting Information: **DUE TO COVID-19 CONCERNS, THIS SERIES WILL BE PRESENTED ONLINE VIA WEBEX ONLY.** Please see the [USHP website](#)

Credit Hours: Through attending this program, up to 12.0 contact hours (0.12 CEUs) can be attained. Participants must register and pay for the series, obtain individual session CE codes, and complete evaluation surveys for each day attended. The links to these surveys are available on the USHP website and must be completed within 7 days of each day of CE attendance. A participation code will be required to get credit for each day. You must register and pay for the CE Series by 04/18/2020.

Special Accommodations: If you are in need of any special accommodation, please contact us at the addresses below a minimum of 2 days prior to the program in order to make arrangements.

Commercial Support: No commercial support was received for this program.

Questions? Emma Jones (emma.jones@hci.utah.edu), or Jennifer Bishop (Jennifer.Bishop@MountainStarHealth.com)



The Utah Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.